selected publications
-
Journal Article
- Quality of life and adverse events: prognostic relationships in long-term ovarian cancer survival. Journal of the National Cancer Institute. 2021
- A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Annals of Oncology. 2017